secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001437749-24-030845
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences agrees to $40M SEC settlement; ReTHINK Phase 3 top-line due by year end
--------------------------------------------------------------------------------

- Agreed to pay $40M civil penalty to SEC for negligent disclosures related to Phase 2b study; DOJ not expected to charge company.
- ReTHINK Phase 3 (804 patients, 77 sites) completed last patient visit; top-line results expected before year end 2024.
- ReFOCUS Phase 3 (1,125 patients) results expected mid-2025; DSMB recommended program continuation without modification.
- Separated CEO and Board Chair roles as part of governance enhancements; Rick Barry remains CEO.
- Nearly 90% of Phase 3 patients elected open-label extension trial; Phase 2 data showed mild patients stable over 24 months on simufilam.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/0001437749-24-030845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/sava20241007_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer